What changed from existing technology?
This study shows that detecting cancer cells in the blood can help identify patients with a more aggressive form of multiple myeloma, improving how doctors predict the disease's progression.
This is the first study to show that circulating tumor cells can refine the genomic risk stratification in multiple myeloma, adding new information about disease dissemination beyond standard genomic markers.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
disease monitoring. We retrospectively analyzed 631 MM patients from the NICHE cohort (NCT04645199) who underwent CTC assessment across disease phases. Among
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
CTC assessment may help refine risk stratification and monitor residual disease in multiple myeloma patients, potentially guiding treatment decisions and follow-up strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.